SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRC SciSparc Ltd.

Closed Good Friday 04-17 16:00:00 EDT

0.2826

+0.0120

+4.43%

盘后0.2696

-0.0130-4.60%

19:59 EDT

High0.2833	Low0.2611	Vol79.39K
Open0.2800	D1 Closing0.2706	Amplitude8.20%
Mkt Cap3.06M	Tradable Cap3.06M	Total Shares10.83M
T/O21.58K	T/O Rate0.73%	Tradable Shares10.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SPRC","market":"US","secType":"STK","nameCN":"SciSparc Ltd.","latestPrice":0.2826,"timestamp":1744920000000,"preClose":0.2706,"halted":0,"volume":79391,"hourTrading":{"tag":"盘后","latestPrice":0.2696,"preClose":0.2826,"latestTime":"19:59 EDT","volume":3179,"amount":916.8418,"timestamp":1744934355345},"delay":0,"floatShares":10828251,"shares":10828251,"eps":-5.008752,"marketStatus":"Closed Good Friday","change":0.012,"latestTime":"04-17 16:00:00 EDT","open":0.28,"high":0.2833,"low":0.2611,"amount":21584.32094715,"amplitude":0.08204,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.008752,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.2706,"preHourTrading":{"tag":"盘前","latestPrice":0.29,"preClose":0.2711,"latestTime":"09:26 EDT","volume":248,"amount":71.42599888000001,"timestamp":1744896384568},"postHourTrading":{"tag":"盘后","latestPrice":0.2696,"preClose":0.2826,"latestTime":"19:59 EDT","volume":3179,"amount":916.8418,"timestamp":1744934355345},"volumeRatio":0.7210428517738549},"requestUrl":"/m/hq/s/SPRC","defaultTab":"news","newsList":[{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SEEL","OPTHF","PHRRF","BETRF","QNTM","MYCOF","IXHL","SPRC","BK4547","FLHLF","MDXXF","BK4139","BK4539","ATAI","RLMD","PBM","CMPS","NUMIF","BK4007","MIRA","RVVTF","GHRS","CMND","ALID","AGNPF","SILO","KTTA","ENTBF","DRUG","CYBN","PSYGF","MNMD","SNPX","BK4168","NRXP","BK4202"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENVB","RLMD","MYCOF","BK4202","SILO","NUMIF","SNPX","DRUG","FLHLF","MNMD","BK4168","ATAI","RVVTF","KTTA","BK4539","BETRF","AGNPF","CMND","PBM","NRXP","CYBN","CMPS","SPRC","ENTBF","QNTM","SEEL","BK4139","PSYGF","BK4007","GHRS","IXHL","MDXXF","PHRRF","ALID","OPTHF","BK4547","MIRA"],"gpt_icon":0},{"id":"2518486225","title":"BRIEF-Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction","url":"https://stock-news.laohu8.com/highlight/detail?id=2518486225","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518486225?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:32","pubTimestamp":1741609945,"startTime":"0","endTime":"0","summary":"BRIEF-Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addictionMarch 10  - Clearmind Medicine Inc CMND.O:SCISPARC-CLEARMIND COLLABORATION LEADS TO PUBLICATION OF PATENT APPLICATION FOR COCAINE ADDICTION PSYCHEDELIC COMBINATION TREATMENT IN SOUTH KOREASource text: nGNX98FWdxFurther company coverage: CMND.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUA8LZPT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CMND","SPRC"],"gpt_icon":0},{"id":"2518424063","title":"Scisparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea","url":"https://stock-news.laohu8.com/highlight/detail?id=2518424063","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518424063?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:45","pubTimestamp":1741607100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUA8LZPT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","CMND","SPRC"],"gpt_icon":0},{"id":"2518223006","title":"SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea","url":"https://stock-news.laohu8.com/highlight/detail?id=2518223006","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518223006?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:45","pubTimestamp":1741607100,"startTime":"0","endTime":"0","summary":"The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These results followed an earlier experiment in which animals treated with MEAI exhibited a significant reduction in cocaine-induced craving.Building on these findings, further research assessed whether MEAI’s effect on drug-seeking behavior extends to natural rewards, as reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards, such as sucrose. This suggests that MEAI’s effect on drug craving is not linked to the general reward system but rather specifically targets drug-related compulsions.This latest publication adds to multiple patent applications already filed in the U.S. and other global territories as part of the ongoing SciSparc-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-clearmind-collaboration-leads-publication-114500371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND","SPRC"],"gpt_icon":0},{"id":"2518247958","title":"Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247958","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247958?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:27","pubTimestamp":1741606020,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, March  10, 2025  (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on discovery and d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039620/0/en/Clearmind-Medicine-Announces-Publication-of-Patent-for-Cocaine-Addiction-Psychedelic-Combination-Treatment-in-South-Korea.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"gpt_icon":0},{"id":"2516631221","title":"BRIEF-SciSparc Signs Definitive Agreement To Sell Mitocarex","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631221","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631221?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 22:30","pubTimestamp":1741012224,"startTime":"0","endTime":"0","summary":"BRIEF-SciSparc Signs Definitive Agreement To Sell MitocarexMarch 3 (Reuters) - Scisparc Ltd SPRC.O:SCISPARC SIGNS DEFINITIVE AGREEMENT TO SELL MITOCAREX, COMPUTATIONAL DRUG DISCOVERY COMPANY TARGETING","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA7PDTWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"2516636018","title":"SciSparc signs definitive agreement to sell MitoCareX to N2OFF","url":"https://stock-news.laohu8.com/highlight/detail?id=2516636018","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516636018?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:36","pubTimestamp":1741009008,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)has signed a definitive agreement to sell its entire ownership interest in MitoCareX Bio to N2Off (NITO). SciSparc currently owns 52...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-signs-definitive-agreement-to-sell-mitocarex-to-n2off?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-signs-definitive-agreement-to-sell-mitocarex-to-n2off?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NITO","SPRC","BK4093","BK4139","BK4007"],"gpt_icon":0},{"id":"2516351956","title":"Scisparc Signs Definitive Agreement to Sell Mitocarex, Computational Drug Discovery Company Targeting Resistant Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2516351956","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516351956?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:25","pubTimestamp":1741008300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA7PDTWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"2516635427","title":"SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635427","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635427?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:25","pubTimestamp":1741008300,"startTime":"0","endTime":"0","summary":"SciSparc will sell its MitoCareX’s shares for $700,000 and exchange its remaining shares for common stock in N2OFF. SciSparc Ltd. has entered into a Securities Purchase and Exchange Agreement with N2OFF, under which SciSparc and other sellers, including Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, will transfer full ownership of MitoCareX Bio Ltd. to N2OFF. As part of the agreement, SciSparc will sell 4,961 shares of MitoCareX to N2OFF for $700,000 and exchange its remaining shares for common stock in N2OFF. In total, SciSparc and the other sellers will receive N2OFF common stock equivalent to 40% of the company’s fully diluted capital stock. The transaction is subject to certain conditions, including approval of N2OFF’s shareholders. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with its board restructured under N2OFF’s control.SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-signs-definitive-agreement-sell-132500084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","SPRC","BK4139"],"gpt_icon":0},{"id":"2514155353","title":"Scisparc Ltd: on Feb 25, Co Entered Securities Purchase Agreements to Sell, Issue to Debentures in Aggregate Principal Amount of $4.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514155353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514155353?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:37","pubTimestamp":1740692251,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI2BD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"2514807756","title":"SciSparc extends $2M loan to support AutoMax growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2514807756","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514807756?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:50","pubTimestamp":1740664250,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)has entered into a loan agreement with AutoMax Motors to provide a $2 million loan. The funding will support AutoMax’s business expa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-extends-2m-loan-to-support-automax-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-extends-2m-loan-to-support-automax-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","SPRC"],"gpt_icon":0},{"id":"2514994807","title":"Scisparc Extends $2 Million Loan to Support Automax's Growth Following Automax’s Entry Into Direct Import of Jac Electric Vehicles","url":"https://stock-news.laohu8.com/highlight/detail?id=2514994807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514994807?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:45","pubTimestamp":1740663912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1BZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRC","BK4007","BK4139"],"gpt_icon":0},{"id":"2514074848","title":"SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles","url":"https://stock-news.laohu8.com/highlight/detail?id=2514074848","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514074848?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:45","pubTimestamp":1740663900,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Feb. 27, 2025  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement with AutoMax Motors Ltd.  to provide a $2 million loan . The funding will support AutoMax's business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd.  electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4.25 million . The Previous Loans were provided in lieu of SciSparc’s obligation to provide a $4.25 million closing financing, in accordance with the merger agreement signed between the parties.In April 2024, SciSparc and AutoMax signed a merger agreement under which SciSparc will acquire 100% of AutoMax, aiming to expand into the automotive sector. The merger is subject to customary closing conditions, including shareholder approvals from bo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-extends-2-million-loan-134500716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"2514276851","title":"N2OFF to Acquire Biotech Firm MitoCareX Bio; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2514276851","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514276851?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 23:16","pubTimestamp":1740582985,"startTime":"0","endTime":"0","summary":"N2OFF  said Wednesday that it signed a definitive deal to acquire the biotech company MitoCareX Bio from owners Alon Silberman, Ciro Leonardo Pierri and SciSparc Under the terms, N2OFF will purchase 4,961 MitoCareX shares from SciSparc for $700,000 and exchange additional shares with the all sellers for stock totaling 40% of its outstanding share capital.N2OFF said the sellers will also be entitled to 30% of its financing proceeds, up to a maximum of $1.6 million, over five years and milestone-based issuances of up to 25% of its common shares.MitoCareX will become a subsidiary of N2OFF after closing of the transaction, which remains subject to approval by N2OFF shareholders, the company said.N2OFF shares were down more than 15% in recent trading Wednesday.Price: 0.52, Change: -0.05, Percent Change: -9.41","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","SPRC","BK4093","NITO","BK4139"],"gpt_icon":1},{"id":"2514855526","title":"N2off Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard to Treat Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2514855526","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514855526?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:29","pubTimestamp":1740580140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA45XPKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4093","NITO","SPRC","BK4139"],"gpt_icon":0},{"id":"2514285568","title":"N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2514285568","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514285568?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:29","pubTimestamp":1740580140,"startTime":"0","endTime":"0","summary":"Neve Yarak, Israel, Feb.  26, 2025  (GLOBE NEWSWIRE) -- N2OFF, Inc.\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for solar energy, energ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3033018/0/en/N2OFF-Signs-Definitive-Agreement-to-Acquire-Next-Gen-Computational-Drug-Discovery-Company-Targeting-Hard-To-Treat-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","SPRC","BK4007","BK4097","LU2286300806.USD","BK4093","NITO","BK4585","GEN"],"gpt_icon":0},{"id":"2512159038","title":"Scisparc Ltd: Suit Included Allegations of Breaches of Fiduciary Duties of Defendants Relating to Prior Acquisition of Pain Clinic Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159038","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159038?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:20","pubTimestamp":1739881230,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nFWN3P912W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"2512159033","title":"Scisparc Ltd: Secures Favorable Settlement in Lawsuit Filed in Feb 2022 Against Six  Former Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159033?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:20","pubTimestamp":1739881230,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nFWN3P912W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"2512159028","title":"Scisparc Ltd: as Part of Settlement, Co Is Entitled to $411,000 Payment From Defendants for Full Dismissal by Co of Alleged Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159028?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:20","pubTimestamp":1739881230,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nFWN3P912W:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scisparc.com","stockEarnings":[{"period":"1week","weight":0.0321},{"period":"1month","weight":-0.2362},{"period":"3month","weight":-0.5282},{"period":"6month","weight":0.233},{"period":"1year","weight":-0.7859},{"period":"ytd","weight":-0.215}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01448},{"month":2,"riseRate":0.25,"avgChangeRate":-0.105855},{"month":3,"riseRate":0,"avgChangeRate":-0.33348},{"month":4,"riseRate":0.25,"avgChangeRate":0.013544},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.101764},{"month":6,"riseRate":0,"avgChangeRate":-0.205264},{"month":7,"riseRate":0,"avgChangeRate":-0.28376},{"month":8,"riseRate":0,"avgChangeRate":-0.43328},{"month":9,"riseRate":0,"avgChangeRate":-0.169119},{"month":10,"riseRate":1,"avgChangeRate":0.257399},{"month":11,"riseRate":0.666667,"avgChangeRate":0.118265},{"month":12,"riseRate":0.333333,"avgChangeRate":0.005952}],"exchange":"NASDAQ","name":"SciSparc Ltd.","nameEN":"SciSparc Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SciSparc Ltd.,SPRC,SciSparc Ltd.股票,SciSparc Ltd.股票老虎,SciSparc Ltd.股票老虎国际,SciSparc Ltd.行情,SciSparc Ltd.股票行情,SciSparc Ltd.股价,SciSparc Ltd.股市,SciSparc Ltd.股票价格,SciSparc Ltd.股票交易,SciSparc Ltd.股票购买,SciSparc Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction